Abstract Stroke induces a catastrophic immune response that involves the global activation of peripheral leukocytes, especially T cells. The human leukocyte antigen-DRα1 domain linked to ) is a partial major histocompatibility complex (MHC) class II construct which can inhibit neuroantigen-specific T cells and block binding of the cytokine/chemokine macrophage migration inhibitory factor (MIF) to its CD74 receptor on monocytes and macrophages. Here, we evaluated the therapeutic effect of DRα1-MOG-35-55 in a mouse model of permanent distal middle cerebral artery occlusion (dMCAO). DRα1-MOG-35-55 was administered to WT C57BL/6 mice by subcutaneous injection starting 4 h after the onset of ischemia followed by three daily injections. We demonstrated that DRα1-MOG-35-55 post treatment significantly reduced brain infarct volume, improved functional outcomes, and inhibited the accumulation of CD4 + and CD8 + T cells and expression of pro-inflammatory cytokines in the ischemic brain 96 h after dMCAO. In addition, DRα1-MOG-35-55 treatment shifted microglia/macrophages in the ischemic brain to a beneficial M2 phenotype without changing their total numbers in the brain or blood. This study demonstrates for the first time the therapeutic efficacy of the DRα1-MOG-35-55 construct in dMCAO across MHC class II barriers in C57BL/6 mice. This MHC-independent effect obviates the need for tissue typing and will thus greatly expedite treatment with DRα1-MOG-35-55 in human stroke subjects. Taken together, our findings suggest that DRα1-MOG-35-55 treatment may reduce ischemic brain injury by regulating post-stroke immune responses in the brain and the periphery.
Introduction
Post-stroke inflammation includes a rapid activation of microglia followed by the infiltration of peripheral inflammatory cells, including neutrophils, T cells, B cells, and macrophages [1] [2] [3] [4] . The influx of these immune cells is known to exacerbate the brain injury and deteriorate stroke outcomes [5, 6] . Therefore, reducing the brain infiltration of peripheral immune cells and reducing cerebral inflammation after stroke may represent effective therapeutic strategies [7] .
T cells are major contributors to post-stroke inflammation. It has been shown that the activation and infiltration of T cells into the brain contribute to the brain infract and neurological deficit induced by middle cerebral artery occlusion (MCAO) [8] [9] [10] . Mice lacking T lymphocytes exhibited reduced infract size and improved neurological function after stroke [8, 9, 11] . Although the mechanisms for T cell activation after brain ischemia is not completely clear, one explanation is that circulating T cells are activated when encountering myelin antigens leaked through a damaged blood-brain barrier (BBB). Activated T cells may release inflammatory cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor α (TNF-α), which, in turn, propagate an autoaggressive immune response, facilitate the infiltration of other immune cells into the brain [12] [13] [14] , and aggravate ischemic cell death [8, 15] . Thus, immunotherapy that can inhibit T cell activation and migration may reduce the inflammatory damage to the ischemic brain.
Recombinant T cell receptor (TCR) ligands (RTLs) are molecular constructs comprised of covalently linked α1 and β1 domains of the major histocompatibility complex (MHC) class II molecules with an attached antigenic peptide [10, 11, 16] . Unlike four-domain MHC class II molecules that induce T cell activation, RTLs are partial agonists of TCR and can deviate autoreactive T cell responses [17] [18] [19] [20] . Moreover, RTL constructs can block binding and downstream signaling of the cytokine/chemokine and macrophage migration inhibitory factor (MIF) through its CD74 receptor on monocytes and macrophages [21] (featured on MDLinx.com). RTL treatment has been shown to inhibit the brain-reactive T cells without inducing general immunosuppression [13] . Previous studies demonstrated that RTL treatment can protect against experimental autoimmune encephalomyelitis (EAE) and ischemic brain injury in mice [13, 18, 19, [22] [23] [24] [25] . However, the clinical translation of RTL to stroke treatment is restricted by the requirement for rapid matching of recipient MHC class II with the β1 domains of RTL construct. Recently, a recombinant protein consisting of only the human leukocyte antigen (HLA)-DRα1 domain (without the β1 domain) linked to MOG-35-55 peptide [26] was shown to reduce ischemic brain injury after transient MCAO [27] . Intriguingly, because the DRα1 domain is expressed in all humans, DRα1-MOG-35-55 treatment does not require HLA screening of potential recipients and could be used immediately in patients with acute ischemic injury.
Since many cases of stroke in humans are non-reperfused, we here test the effect of DRα1-MOG-35-55 in a permanent distal MCAO model of stroke. We demonstrate that DRα1-MOG-35-55 given after permanent stroke induction reduces infract size and improve functional outcomes without reversing spleen atrophy after distal middle cerebral artery occlusion (dMCAO). We further showed that DRα1-MOG-35-55 treatment not only reduced the influx of T cells into the ischemic brain but also shifted the microglia/macrophage polarization toward a beneficial M2 phenotype.
Materials and Methods

Murine Model of Permanent Distal MCAO
All animal experiments were approved by the University of Pittsburgh Institutional Animal Care and Use Committee and performed in accordance with the principles outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Male C57/BL6 mice (8-10 weeks, 25-30 g body weight) were purchased from the Jackson Laboratory. Mice were subjected to distal MCAO as described previously [28] . Briefly, mice were anesthetized and cut an incision in the middle of neck. The left carotid common artery was ligated. The distal part of the middle cerebral artery was then coagulated by bipolar electrocautery (Bipolar Coagulator, Codman & Shurtleff, Inc., Randolph, MA, USA). Cerebral blood flow was monitored, and animals with less than 70% original cerebral blood flow were excluded.
Drug Treatment
Mice that were subjected to dMCAO were randomized. DRα1-MOG-35-55 (100 μl, 1 mg/mL) or the same volume of vehicle (Tris-HCl, pH = 8.5) was administered by subcutaneous injection starting 4 h after the onset of ischemia, followed by daily administration for another 3 days.
Measurements of Infarct Volume
Infarct volume was measured by 2.3.5-triphenyltetrazolium chloride (TTC) staining as previously described [28] . Briefly, brains were removed and sliced to generate 1-mm sections. Sections were stained in pre-warmed 2% 2.3.5-triphenyltetrazolium chloride (Sigma-Aldrich) in saline for 10 min and then fixed in 4% paraformaldehyde in PBS, pH 7.4. National Institutes of Health ImageJ software was used to analyze the infarct volume by a person blinded to the experiment group. The actual infarct volume was corrected as the volume of the contralateral hemisphere minus the non-infarct volume of the ipsilateral hemisphere.
Rotarod Test
The rotarod test was performed to access motor function as previously described [29] . Animals were placed on a rotating rod at an accelerating speed from 4 to 120 rpm over 120 s. The latency to fall was recorded. Training (three trials each day) was performed 3 days before surgery. The mean of three trials on the day before surgery was recorded for each mouse and was used as the pre-stroke baseline value. Each mouse was tested three times on days 1, 3, 5, 7, and 10 after stroke. The mean value of latency to fall was calculated and analyzed.
Adhesive Removal Adhesive removal was performed to access sensorimotor function as described previously [30] . Briefly, mice were habituated in the testing box for 1 min and then gently covered with an adhesive tape with equal pressure on the right paw of each mouse. The time to contact and the time to remove the tape were recorded with a maximum duration of 120 s. Pre-training began 3 days before surgery and consisted of three trials each day. The mean of three trials on the day before surgery was recorded as the pre-stroke baseline value. Each mouse was tested for three trials on days 1, 3, 5, and 7. Data were expressed as the time to contact and the time to remove the tape on each testing day.
Modified Garcia Score The modified Garcia score system was established to access sensorimotor function [31] . Briefly, an observer blinded to the experimental group evaluated the performance of each mouse at days 1, 3, 5, 7, and 10 post surgery. The score consists of five tests: body proprioception, vibrissae touch, limb symmetry, lateral turning, and forelimb walking with scores of 0-3 for each test (maximum score equal to 15). Baseline was recorded on each mouse on the day before surgery.
RT-PCR
Total RNA was isolated from sham brains and ischemic brains using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instruction; 1 μg of RNA was used to synthesize the first strand of cDNA using the Superscript First-Strand Synthesis System for RT-PCR (Invitrogen). PCR was performed on the Opticon 2 Real-Time PCR Detection System (Bio-Rad) using corresponding primers and SYBR gene PCR Mix (Invitrogen). Primers used are as follows: IL-1β, forward primer GCCCATCCTCTGTGACTCGA and reverse primer AGCTCATATGGGTCCGACAG; IL-17, forward primer TCCCTCTGTGATCTGGGAAG and reverse primer CTCGACCCTGAAAGTAAGG; TNF-α, forward primer AGAAGTTCCCAAATGGCCTC and reverse primer CCACTTGGTGGTTTGCTACG; and IFN-γ, forward primer GCGTCATTGAATCACACCTG and reverse primer T G A G C T C AT T G A AT G C T T G G . E x p r e s s i o n o f glyceraldehyde 3-phosphate dehydrogenase (GAPDH) messenger RNA (mRNA) served as an internal control. The expression levels of the mRNAs were reported as fold change vs. sham control.
Tissue Preparation and Immunohistochemistry
Brain tissue was prepared and subjected to immunohistochemistry staining as before [32, 33] . Primary antibodies include goat anti-CD206 (1:100; R&D System, Minneapolis, MN, USA), rabbit anti-Iba1 (1:1000; Wako, Richmond, VA, USA), F4/80 (1:200; BioLegend). All images were processed with ImageJ for cell counting. Averaged cell numbers were calculated from two randomly selected microscopic fields, and three consecutive sections were analyzed for each brain. Data are expressed as mean numbers of cells per square millimeter.
Single Cell Preparation from the Spleen, Blood, and Brain
The spleen, blood, and brain were collected after dMCAO, and single-cell suspensions were prepared for flow cytometry analysis. Briefly, the brain was first dissociated into a singlecell suspension by using gentleMACS Dissociators (Miltenyl Biotec) following the manufacturer's instruction. The suspension was passed through a 70-μm cell strainer, resuspended in 30% Percoll (GE Health), and overlaid to 3 mL with 70% Percoll. Cells were separated at 500 g for 30 min at 18. The cells in the interface were collected and washed before staining. Peripheral blood was obtained from mice by cardiac puncture, and the red blood cells were lysed by ammoniumchloride-potassium lysis buffer (Sigma-Aldrich). Spleens from individual sham and dMCAO mice were removed, and single-cell suspensions were isolated, followed by lysis of red blood cells using the ammonium-chloride-potassium lysis buffer. Isolated cells were resuspended and stained. 
Flow Cytometry
Cells were stained with fluorophore-labeled mouse CD3, CD4, CD8, CD45, CD11b, CD19, or NK1.1 antibodies following the manufacturer's instructions (eBioscience). Flow cytometric analysis was performed using a flow cytometer (BD Biosciences).
Statistical Analysis
All data were reported as mean ± SD. Comparison of means between two groups was accomplished by Student's t test (two tailed). Differences in means among multiple groups were analyzed using one-or two-way analysis of variance followed by the Bonferroni test. A p value <0.05 was considered statistically significant. (Fig. 1a, b, 30 .18 ± 3.19 in vehicle-treated (n = 12) vs. 20.76 ± 2.72 in DRα1-MOG-35-55-treated (n = 12) mice, p < 0.05). We also evaluated the effect of DRα1-MOG-35-55 treatment on stroke-induced splenic atrophy. As expected, the size of the spleen and the number of cells in the spleen were significantly reduced at 4 days after dMCAO. However, the DRα1-MOG-35-55-treated and vehicle-treated mice showed comparable sizes of the spleen (Fig. 1c) . Similarly, there was no difference in the number of splenocytes between the vehicle-treated and DRα1-MOG-35-55-treated mice at 4 days post dMCAO (Fig. 1d ).
DRα1-MOG-35-55 Treatment Significantly Augments
Sensorimotor Functions After dMCAO In order to evaluate the effect of DRα1-MOG-35-55 on functional outcomes after dMCAO, a battery of neurological behavior tests was performed. The DRα1-MOG-35-55-treated group exhibited significant improvement compared with the vehicle-treated group in the rotarod test (Fig. 2a) . Similarly, mice with DRα1-MOG-35-55 treatment showed better performance in the adhesive removal test (Fig. 2b) . The Garcia score was also used to measure the behavioral deficits (Fig. 2c) . Mice in the vehicle treatment group showed deficits in body proprioception, limb symmetry, lateral turning, and forelimb walking at different times after stroke, which were ameliorated by DRα1-MOG-35-55 treatment (Fig. 2c) . These results indicate that DRα1-MOG-35-55 treatment improved the short-term behavioral functions after dMCAO. Brain After Distal MCAO In order to evaluate the effect of DRα1-MOG-35-55 treatment on cerebral inflammation after dMCAO, we measured the mRNA expression of several proinflammatory cytokines in the ischemic brain using RT-PCR at 4 days after dMCAO. As shown in Fig. 3a , b, DRα1-MOG-35-55 treatment significantly reduced the expression of IL-1 and IL-17 in ipsilateral hemispheres compared to that of vehicle-treated mice. There was no significant difference in the expression of TNF-α (Fig. 3c) or IFN-γ (Fig. 3d) between the DRα1-MOG-35-55 treatment and the vehicle treatment.
DRα1-MOG-35-55 Treatment Reduces the Gene Expression of Inflammatory Cytokines in the Ischemic
DRα1-MOG-35-55 Treatment Inhibits Influx of T Lymphocytes After dMCAO
We then evaluated the effects of DRα1-MOG-35-55 treatment on immune cell infiltration into the ischemic brain at 4 days after dMCAO. The brain tissue was collected from the (Fig. 4a) . The results showed that the DRα1-MOG-35-55 treatment markedly decreased the number of CD3 + CD4 + T cells (Fig. 4b, c) and CD3 + CD8 + T cells (Fig. 4d, e) in the ischemic hemisphere compared to those of the vehicle-treated mice. Similarly, the number of CD3 + CD4 + T cells and CD3 + CD8 + T cells in the blood of DRα1-MOG-35-55-treated mice was significantly decreased compared with that of vehicle-treated mice (Fig. 4f, g ). In contrast, there was no difference in the numbers of CD4 + and CD8 + T cell populations in the spleen between the DRα1-MOG-35-55-treated and vehicle-treated groups (Fig. 4h, i) . (Fig. 5a) . The total number of macrophages and microglia showed no difference between DRα1-MOG-35-55-treated and vehicle-treated mice at day 4 after dMCAO ( Fig. 5b, c) . Immunofluorescent staining of F4/80 confirmed comparable numbers of F4/80 + macrophages in the ischemic areas in DRα1-MOG-35-55-treated and vehicle-treated mice (Fig. 5d, e) . Interestingly, the expression of the M2 marker, CD206, was significantly upregulated in Iba1 + microglia/macrophage in DRα1-MOG-35-55-treated mice as compared to vehicle-treated controls (Fig. 5f, g ). These results suggest that although DRα1-MOG-35-55 does not reduce the number of activated microglia/macrophage after dMCAO, it can shift microglia/macrophage toward a beneficial M2 phenotype. Similar to the brain, the number of macrophages in the blood and spleen showed no difference between DRα1-MOG-35-55-treated and vehicle-treated mice 4 days after dMCAO (Fig. 5h, i) . (Fig. 6a) and spleen (Fig. 6c) between the vehicle and DRα1-MOG-35-55 treatments at 4 days post dMCAO. The number of B cells in the blood was significantly decreased in the DRα1-MOG-35-55-treated mice compared to vehicle-treated controls (Fig. 6b) . DRα1-MOG-35-55 treatment did not have an effect on the number of NK cells in the brain, blood, and spleen after dMCAO (Fig. 6d-f ).
Discussion
Stroke is considered a classical acute brain injury that is closely associated with inflammation both inside and outside the brain. Interventions aimed at harnessing post-stroke inflammation are considered as promising avenues for stroke management [34] . Our study here demonstrates that the treatment of permanent dMCAO in HLA class II-mismatched C57BL/6 mice with DRα1-MOG-35-55 can significantly reduce the infarct size, block the infiltration of T cells into the ischemic brain, shift microglia/macrophage to a beneficial M2 phenotype, and enhance functional outcomes. These results extend Fig. 6 DRα1-MOG-35-55 treatment has a minimal effect on B cell and NK cell populations in the ischemic brain 4 days after dMCAO. Cells were isolated from the ischemic hemisphere, the blood, and the spleen 4 days after ischemia. Flow cytometry was used to evaluate the number of B cells (a-c) and NK cells (df) in the ischemic brain, blood, and spleen. n = 3 for the vehicle group and n = 4 for the DRα1-MOG-35-55 group. Data are presented as mean ± SD. *p < 0.05, by unpaired Student's t test our previous studies showing treatment of transient MCAO with RTL1000 constructs in which efficacy was limited to MHC class II-matched HLA-DR2-Tg mice.
DRα1-MOG-35-55 as well as RTL were initially used as a therapy for EAE, a murine model for multiple sclerosis, which may involve increased CD4 + T cell responses against myelin antigens [18, 35] . Antigen-specific T cell responses are also prominent after stroke [36] . In particular, the infiltration of MOG-specific T cells into the brain was observed after experimental stroke [12] . Similarly, in vivo expansion of myelinreactive T cells was detected in the cortical spinal fluid (CSF) of stroke patients [37] . Moreover, the increased T cell reactivity to myelin was correlated with stroke severity and worse outcome at follow-up [37, 38] . This might explain why blocking the MOGspecific T cells with DRα1-MOG-35-55 could reduce local inflammation and provide protection to the ischemic brain.
Our data demonstrated a strong capacity of high macrophages into the ischemic brain. However, in the permanent stroke model, we did not observe the same phenomenon. This discrepancy might be due partially to the different temporal files of macrophage infiltration in these two stroke models. A comparison study showed that the influx of macrophages into the ischemic brain after permanent MCAO is relatively delayed as compared to transient MCAO [39] . Moreover, as revealed by bone marrow transplant chimeras, the majority of macrophage-like cells in the ischemic brain are activated microglia but not blood-derived macrophages, especially during the first few days following permanent cerebral ischemia [40] .
Despite the lack of effect of DRα1-MOG-35-55 on the number of activated microglia/macrophages, our data demonstrated an effect of DRα1-MOG-35-55 on promoting M2 polarity of these phagocytes. It is well known that microglia/macrophages are highly dynamic cells that can assume different functional status under stimulation. Specifically, the M1-like microglia/ macrophages could accentuate brain damage while the M2-like microglia/macrophages preserved brain tissue after ischemic injury [41] . Our previous study has revealed a gradual shifting of microglia/macrophage polarity toward M2 with the progress of ischemic brain injury [42] . Therefore, the effect of DRα1-MOG-35-55 to shift microglia/macrophage polarity toward a beneficial M2-like phenotype may partially contribute to the protection of the ischemic brain. Since microglia/macrophage phenotype change is also common in other forms of CNS injuries [43] , the effect of DRα1-MOG-35-55 on other neurological disorders such as intracerebral hemorrhage needs to be examined.
It is also noted that although DRα1-MOG-35-55 treatment ameliorated splenic atrophy in the transient model of stroke, it showed no effect on the permanent model. This might be due to the less severe splenic atrophy in the distal model compared with the transient model. Consistent with this observation, DRα1-MOG-35-55 showed very little effect on the number of different immune cells in the spleen. Therefore, the circulating T cells might be the main peripheral target for DRα1-MOG-35-55.
In summary, this study shows the therapeutic effect of DRα1-MOG-35-55 in a permanent model of stroke and elucidates the immunomodulatory effect of this drug on T cells and microglia/macrophages. Based on the potency of DRα1-MOG-35-55 to reduce acute brain infarct in both transient [27] and permanent models of stroke and its ability to treat across MHC barriers thus obviating need for tissue typing in human stroke subjects, further studies are warranted to explore its long-term effects on brain integrity and functional recovery after stroke.
